TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24643639
Drug: JET combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: JET combination therapy
Study: 15702515
Drug: Rizatriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan nasal spray (5 mg)
Study: 15702515
Drug: Oral rizatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rizatriptan tablet (5 mg)
Study: 12848628
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg/day for 3 weeks)
Study: 10700887
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy for locally unresectable cancer in the oral cavity, pharynx, and nose and paranasal sinus
Study: 10700887
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus adjuvant chemotherapy for advanced N stage nasopharyngeal cancer
Study: 10700887
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy for advanced T stage nasopharyngeal cancer
Study: 10700887
Drug: Neoadjuvant and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant and/or concurrent chemoradiotherapy for T2 and T3 laryngeal and hypopharyngeal cancer
Study: 9038610
Drug: recombinant interleukin-2
Normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: recombinant interleukin-2 (rIL-2) with chemotherapy (5-fluorouracil and leucovorin)
Study: 1665285
Drug: Zileuton (A-64077)
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton (A-64077) 600 mg q.i.d. for 14 days
Study: 16649820
Drug: Quetiapine (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (pooled doses)
Study: 12414914
Drug: weight-adjusted heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: weight-adjusted heparin
Study: 12414914
Drug: oral compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral compounds
Study: 10400458
Drug: Antioxidant infusion
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant infusion containing tocopherol and ascorbate
Study: 10400458
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antioxidant infusion)
Study: 8524969
Drug: brotizolam 0.25
Normalized name: brotizolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: brotizolam 0.25 mg
Study: 23982942
Drug: Telephone survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone survey administration (n = 99)
Study: 23072847
Drug: Yoyo Bitters
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoyo Bitters (1206.5 mg/kg)
Study: 23072847
Drug: Yoyo Bitters
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoyo Bitters (804.3 mg/kg)
Study: 12407324
Drug: Conventional hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional hormone replacement therapy (HRT)
Study: 2258349
Drug: Pefloxacin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (oral treatment for a mean duration of 13 days)
Study: 2258349
Drug: Ceftazidime (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (intravenous treatment for a mean duration of 10 days)
Study: 30674315
Drug: Maternal pre-pregnancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal pre-pregnancy BMI and weekly gestational weight gain
Study: 30674315
Drug: Weekly gestational
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly gestational weight gain
Study: 22819555
Drug: lycopene-rich diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: lycopene-rich diet (224-350 mg lycopene/week)
Study: 22819555
Drug: lycopene supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: lycopene supplement (70 mg lycopene/week)
Study: 22819555
Drug: control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control diet (<10 mg lycopene/week)
Study: 14628939
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) treatment
Study: 2938886
Drug: Combined pill
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pill (oral contraceptive)
Study: 2938886
Drug: Progestin-only pill
Normalized name: Prostin E2 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin-only pill
Study: 2938886
Drug: DMPA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA and progestin-only treatment
Study: 30032176
Drug: Polyphenol-rich extract
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich extract from grape and blueberry (PEGB) 600 mg/day for 6 months
Study: 27264945
Drug: Clonidine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 3 µg per kg
Study: 22226008
Drug: Treatment combinations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment combinations including insulin
Study: 22226008
Drug: Treatment combinations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment combinations including thiazolidinediones
Study: 22226008
Drug: Treatment combinations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment combinations including sulphonylureas
Study: 20855825
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg and Fulvestrant 250 mg
Study: 15844709
Drug: INF alfacon‐1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: INF alfacon‐1, 15 microg three times per week, plus ribavirin, 1 g/day
Study: 15844709
Drug: IFN‐alpha2b, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha2b, 3 million units three times per week, plus ribavirin, 1 g/day
Study: 8659037
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment (group 1)
Study: 8659037
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and estrogens in addition to radiation (group 2)
Study: 8659037
Drug: Drugs and
Normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs and estrogens (group 3)
Study: 1467075
Drug: Extradural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural bupivacaine 10 ml
Study: 1467075
Drug: Extradural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural saline 10 ml
Study: 1467075
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no extradural injection)
Study: 6329021
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg orally every 6 hours
Study: 6329021
Drug: Conventional alkali
Normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional alkali therapy
Study: 28874133
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg, 3 times daily)
Study: 26905220
Drug: BNP-guided heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP-guided heart failure treatment
Study: 21715446
Drug: BNP-guided heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP-guided heart failure treatment (responders)
Study: 21715446
Drug: BNP-guided heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP-guided heart failure treatment (non-responders)
Study: 8444538
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin
Study: 2804250
Drug: Methylprednisolone phosphate
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone phosphate (doses between 16 and 1000 mg)
Study: 31308191
Drug: MDMA-assisted psychotherapy
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-assisted psychotherapy (8-week course, including two therapy sessions with MDMA)
Study: 25861737
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 671800 50 mg bid
Study: 25861737
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 671800 200 mg bid
Study: 25861737
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 671800 400 mg bid
Study: 25861737
Drug: Fluticasone 220
Normalized name: fluticasone 220 mcg/inh inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 220 μg bid
Study: 25861737
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg qd
Study: 23471101
Drug: Niccine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niccine 40 μg
Study: 21660523
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of tranexamic acid (2.5 g in 250 ml normal saline)
Study: 11280365
Drug: Bone grafting
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone grafting and implant placement (graft group)
Study: 11280365
Drug: Modified implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified implant placement with no bone grafting (trial group)
Study: 11280365
Drug: Optimized complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized complete dentures (no‐implant group)
Study: 9594320
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose urokinase (22,000 IU/kg, total dose not lower than 1.2 million IU)
Study: 9594320
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose urokinase (30,000 IU/kg, total dose not more than 2.4 million IU)
Study: 1900094
Drug: Danazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (200 mg/day)
Study: 27480103
Drug: Cobimetinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobimetinib (60 mg once daily for 21 days followed by a 7-day rest period in each 28-day cycle) plus vemurafenib (960 mg twice daily)
Study: 27480103
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus vemurafenib (960 mg twice daily)
Study: 24740547
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine (specific dosage and duration not mentioned)
Study: 20093351
Drug: ECisF (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECisF (epirubicin 60 mg/m², cisplatin 60 mg/m², 5-FU 200 mg/m² by daily 24-h infusion)
Study: 20093351
Drug: FEC (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC (5-FU 600 mg/m², epirubicin 60 mg/m², cyclophosphamide 600 mg/m²)
Study: 18505852
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg TMC207
Study: 18505852
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg TMC207
Study: 18505852
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg TMC207
Study: 9310010
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg isoniazid (INH)
Study: 18505852
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampin (RIF)
Study: 15920220
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg orally the evening before surgery and 4 mg IV 15 min before subarachnoid anesthesia
Study: 8115316
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg daily for 1 month)
Study: 2960694
Drug: Thromboxane receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboxane receptor antagonist BM 13.177 and thromboxane synthase inhibitor dazoxiben
Study: 21118410
Drug: Dual non‐parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual non‐parenteral combination therapy (including bosentan, sitaxentan, ambrisentan, iloprost, and sildenafil)
Study: 21118410
Drug: Dual non‐parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual non‐parenteral combination therapy
Study: 19693799
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 6 mg alone
Study: 19693799
Drug: Trimethoprim 200
Normalized name: trimethoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 200 mg twice daily
Study: 9755355
Drug: Serotonergic antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic antidepressants (e.g., selective serotonin reuptake inhibitors)
Study: 9755355
Drug: Noradrenergic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic and mixed serotonergic/noradrenergic tricyclic antidepressants
Study: 20631574
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone
Study: 19551680
Drug: Macular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macular laser photocoagulation (MP) after intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Study: 19551680
Drug: Macular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macular laser photocoagulation (MP) concomitant with intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Study: 19551680
Drug: Only intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Study: 2156476
Drug: Ganciclovir, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir, 2.5 mg/kg body weight every 8 hours for 14 days
Study: 396054
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 20 mg/kg praziquantel
Study: 396054
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 50 mg/kg praziquantel
Study: 30121774
Drug: Good glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good glycemic control (HbA1c < 6.5%, FPG < 6.1 mmol/L)
Study: 30121774
Drug: Insufficient glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufficient glycemic control (HbA1c < 6.5%, FPG ≥ 6.1 mmol/L or HbA1c ≥ 6.5%, FPG < 6.1 mmol/L)
Study: 30121774
Drug: Poor glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor glycemic control (HbA1c ≥ 6.5%, FPG ≥ 6.1 mmol/L)
Study: 30121774
Drug: Insulin-exposed group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-exposed group
Study: 30121774
Drug: Insufficient glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufficient glycemic control with insulin exposure
Study: 23419401
Drug: Resistant maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant maltodextrin (RMD) 9 g in tea, taken three times daily for 12 weeks
Study: 16172203
Drug: Olanzapine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (7.5 to 30 mg per day)
Study: 16172203
Drug: Perphenazine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (8 to 32 mg per day)
Study: 16172203
Drug: Quetiapine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (200 to 800 mg per day)
Study: 16172203
Drug: Risperidone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1.5 to 6.0 mg per day)
Study: 16172203
Drug: Ziprasidone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (40 to 160 mg per day)
Study: 8867876
Drug: ZK 93426
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 93426 (0.04 mg; 0.04 ml/kg)
Study: 8867876
Drug: Scopolamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.5 mg; 1 ml)
Study: 1363719
Drug: sulglycotide +
Normalized name: sulglicotide
DrugBank: Sulglicotide (DB13299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulglycotide + H2-antagonists
Study: 6094445
Drug: Cefotaxime 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 3 g intravenously perioperatively
Study: 6094445
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without prophylactic antibiotics
Study: 30561539
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg GMZ2-CAF01
Study: 30561539
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg GMZ2-CAF01
Study: 28329753
Drug: High-intensity training
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity training (twice a week for 90 min with increasing loads)
Study: 24108779
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml of DTaP
Study: 24108779
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of DTaP
Study: 17554217
Drug: Tipranavir (TPV)
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tipranavir (TPV) 500 mg twice daily or 1000 mg twice daily with ritonavir 100 mg twice daily
Study: 17554217
Drug: High-dose TPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TPV/r
Study: 17554217
Drug: Low-dose TPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose TPV/r
Study: 11181397
Drug: Intravenous itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous itraconazole for 7 days followed by oral itraconazole solution at 200 mg twice daily for 14 days
Study: 11181397
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution at 200 mg once daily for 14 days
Study: 11181397
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution at 200 mg twice daily for 14 days
Study: 11181397
Drug: Intravenous itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous itraconazole for 7 days followed by oral itraconazole solution
Study: 1350340
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo with clonidine
Study: 2863295
Drug: Fenoldopam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 200 mg
Study: 2863295
Drug: Fenoldopam (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (various doses)
Study: 29659539
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein concentrate (1.15 and 0.26 g/kg on game and training days, respectively)
Study: 29659539
Drug: Energy‐matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy‐matched placebo (1.37 and 0.31 g/kg of carbohydrate on game and training days, respectively)
Study: 26757216
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg citalopram
Study: 24578545
Drug: Healthy control
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy control subjects (no medication)
Study: 22534255
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg orally once daily for 7 days)
Study: 22534255
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg orally once daily for 10 days)
Study: 22534255
Drug: Gemigliptin monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin monotherapy
Study: 22534255
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration with ketoconazole
Study: 22534255
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration with rifampicin
Study: 20824184
Drug: Apoptotic tumor-autologous
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apoptotic tumor-autologous dendritic cell vaccine
Study: 12599083
Drug: IPT +
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPT + daily iron
Study: 12599083
Drug: daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily iron
Study: 10804679
Drug: Self-help manuals,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help manuals, incentives, and social support groups (G)
Study: 3513329
Drug: Foaming antacid
Normalized name: Foaming Antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foaming antacid
Study: 31919501
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy for 1 year
Study: 9639076
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg methylphenidate
Study: 21745792
Drug: Email addresses
Normalized name: human IgG2 monoclonal antibody directed against the mucosal addressin cell adhesion molecule
DrugBank: Ontamalimab (DB15298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Email addresses used for online financial management and daily checked email accounts
Study: 19690278
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anesthesia with 6-mg hyperbaric bupivacaine 0.5%
Study: 19690278
Drug: Bilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral spinal anesthesia with 6-mg hyperbaric bupivacaine 0.5%